来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药

智通财经网2025-12-31

智通财经APP讯，来凯医药-B(02105)发布公告，本集团已在澳大利亚启动LAE103(一种自研的ActRIIB单克隆抗体)的I期单剂量递增研究(SAD研究)的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103(皮下注射)在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595461717?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-31 08:36","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2595461717","market":"sg","top_or_hot":-1,"title":"来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告，本集团已在澳大利亚启动LAE103(一种自研的ActRIIB单克隆抗体)的I期单剂量递增研究(SAD研究)的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103(皮下注射)在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387442.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n来凯医药-B(02105)：LAE103的I期单剂量递增研究完成首例受试者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-31 08:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1387442.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，来凯医药-B(02105)发布公告，本集团已在澳大利亚启动LAE103(一种自研的ActRIIB单克隆抗体)的I期单剂量递增研究(SAD研究)的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103(皮下注射)在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387442.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"来凯医药-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1387442.html","article_id":"2595461717","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595461717","pubTimestamp":1767141407,"columns":[],"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，来凯医药-B 发布公告，本集团已在澳大利亚启动LAE103的I期单剂量递增研究的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项SAD研究的顶线数据。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02105":"来凯医药-B","BK1161":"生物科技"},"translate_title":"Laikai Pharmaceutical-B (02105): Phase I single-dose escalation study of LAE103 completed the first subject dosing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1.5},"content_text":"智通财经APP讯，来凯医药-B(02105)发布公告，本集团已在澳大利亚启动LAE103(一种自研的ActRIIB单克隆抗体)的I期单剂量递增研究(SAD研究)的受试者入组工作。截至本公告日，首位受试者已完成给药。该SAD研究为一项随机、双盲、安慰剂对照研究，旨在评估LAE103(皮下注射)在健康的超重或肥胖症受试者中的安全性、耐受性、药代动力学及药效学特性。本集团目标于2026年第叁季度公布此项SAD研究的顶线数据。本集团致力将此精准疗法引入心血管与代谢疾病中存在重大未满足医疗需求的领域，例如肥胖症、肌少症及心衰等。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595461717","isCrawlerRequest":true}